TPO and autoimmune thrombocytopenic purpura: The GEPTI advises against the use of immunosuppressants for ITP during the COVID pandemic but recommends them as a third-line treatment option outside the pandemic.[48] The 2 recently released ITP medications, fostamatinib and avatrombopag, are less expensive than the 2 TPO-RAs, romiplostim and eltrombopag, which are available in the market for a long period of time.